QuantHealth

Founders and documented locations

QuantHealth was founded in 2020 by Orr Inbar and Arnon Horev, according to the company's page. It works on simulations for drug development. The official website lists addresses in Tel Aviv and in Worcester, Massachusetts. The investment announcement of October 2025 named Cambridge, and an August 2026 report named New York, as its centers of activity in the United States. The company serves pharmaceutical and biotech companies and offers a tool for planning and evaluating development programs. The product is meant for teams that decide how to run a drug trial, which patients to include and which outcomes to measure.

How the system simulates a drug response

According to the Sanofi Ventures announcement, the platform uses real-world data and AI models to produce simulations at the level of the individual patient. It builds digital representations of patients and predicts their response to the treatment being tested. Combining these representations makes it possible to simulate trial results under different assumptions. This way a proposed design can be tested before money is spent on running it. This is not the creation of a new drug, but a prediction of the response to a drug within a defined population, using biological information and clinical information from patient records. The technology page describes a knowledge graph that links a drug to a biological target, a pathway, a cell, an organ and a disease. The model represents a drug by its structure, its target and its clinical context. PhaseV also works on clinical trial design with machine learning. It raised a $50 million Series A in May 2025 and offers tools for adaptive trial design and for improving the makeup of the patient group in real time.

Which decisions can be compared

The website describes changing the inclusion and exclusion criteria for patients, the treatment regimen, drug combinations, dosage, group size and outcome measures. The system also helps choose the indication in which a drug is worth testing, and estimate the pace of patient recruitment. The development team is shown virtual results for the options it chose. The website also lists uses for asset evaluation and for prioritizing a drug portfolio. These are business and research questions built around the same response prediction. The result of a simulation is a prediction by the model, not a measurement from actual trial participants.

Sanofi Ventures and the Series B

On 1 October 2025 the company announced a strategic investment by Sanofi Ventures, the investment arm of Sanofi. The announcement said total funding had reached $30 million, but did not state the amount of this specific investment. It also described a strategic corporate relationship with Sanofi around the use of simulations and digital patient representations. Cris De Luca of Sanofi Ventures was to join the board as an observer. On 4 August 2026 CTech reported a $45 million Series B led by Qumra Capital, with Pitango HealthTech, Sanofi Ventures, Bertelsmann Healthcare Investments and other investors taking part. According to the report, total funding reached $75 million, and the company had about 85 employees.

The evidence the company presents, and its limits

The company's page describes testing the system on trials and shows accuracy figures for predicting outcome measures. The main website publishes examples by disease area, including cancer and inflammatory bowel diseases. These are evaluation materials published by the company, not a general confirmation that every drug or population will be represented with the same accuracy. The investment announcement presents better chances of success, shorter timelines and lower costs as the goals of using the product. The documented activity is the use of predictions to compare protocols and decide where to invest in further research and in gathering evidence.